RecruitingPhase 4NCT06320626
Pharmacokinetic-guided Dosing of Emicizumab
Studying Hemophilia A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kathelijn Fischer
- Principal Investigator
- Study Officials Fischer, Dr, MDUMC Utrecht
- Intervention
- Emicizumab - PK-guided dose reduction(other)
- Enrollment
- 95 enrolled
- Eligibility
- 1 years · MALE
- Timeline
- 2022 – 2026
Study locations (8)
- Radboud University Medical Center, Nijmegen, Gelderland, Netherlands
- Maastricht University Medical Center, Maastricht, Limburg, Netherlands
- Amsterdam University Medical Center, Amsterdam, North Holland, Netherlands
- Leids Universitair Medisch Centrum, Leiden, South Holland, Netherlands
- Erasmus University Medical Center, Rotterdam, South Holland, Netherlands
- HagaZiekenhuis, The Hague, South Holland, Netherlands
- University Medical Center Groningen, Groningen, Netherlands
- University Medical Center Utrecht, Utrecht, Netherlands
Collaborators
Erasmus Medical Center · Amsterdam University Medical Center · Leiden University Medical Center · Radboud University Medical Center · Maastricht University Medical Center · University Medical Center Groningen · HagaZiekenhuis · Dutch Society of Haemophilia Patients
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06320626 on ClinicalTrials.govOther trials for Hemophilia A
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05936580Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for SurgeryOctapharma
- ACTIVE NOT RECRUITINGNCT07161687A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.Pfizer
- RECRUITINGPHASE4NCT06864975Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)Runhui WU
- RECRUITINGPHASE1NCT06579144Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ASwedish Orphan Biovitrum
- RECRUITINGPHASE3NCT06738485Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCSL Behring
- RECRUITINGNCT06684314A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanSanofi
- RECRUITINGNCT07414511Hemophilia A Research ProgramUniversity of Washington
- RECRUITINGEARLY PHASE1NCT06345833Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded StudyUniversity of Minnesota